Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960895 | 1.00 | KDR (0.39) | KDRADORA2AADORA1MAOAPTGS2 | |
| SCHEMBL20528845 | 0.86 | KDR (0.37) | KDRADORA2AADORA1MAOAPTGS2 | |
| SCHEMBL29961031 | 0.85 | KDR (0.33) | KDRADORA2AADORA1PTGS2MTNR1A | |
| SCHEMBL21840753 | 0.85 | KDR (0.33) | KDRADORA2AADORA1PTGS2MTNR1A | |
| SCHEMBL11546612 | 0.75 | MAOA (0.40) | KDRADORA2AADORA1MAOAPTGS2 | |
| SCHEMBL21840762 | 0.74 | KDR (0.30) | KDRADORA2AADORA1 | |
| SCHEMBL29961019 | 0.74 | KDR (0.30) | KDRADORA2AADORA1 | |
| SCHEMBL21840752 | 0.74 | KDR (0.30) | KDRADORA2AADORA1 | |
| SCHEMBL132494 | 0.72 | ESR2 (0.59) | KDRADORA2AADORA1MAOAPTGS2 | |
| SCHEMBL21840751 | 0.72 | CYP19A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155659-B2 | Dimethyl-silyl-bridged-1-substituted-2-indenyl metallocene complexes for olefin polymerization | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2021-10-26 | — | — | US | disclosed |
| US-11155659-B2 | Dimethyl-silyl-bridged-1-substituted-2-indenyl metallocene complexes for olefin polymerization | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2021-10-26 | — | — | US | disclosed |
| EP-3606967-B1 | DIMETHYL-SILYL-BRIDGED-1-SUBSTITUTED-2-INDENYL METALLOCENE COMPLEXES FOR OLEFIN POLYMERIZATION | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2021-08-11 | — | — | EP | disclosed |
| US-20200115478-A1 | DIMETHYL-SILYL-BRIDGED-1-SUBSTITUTED-2-INDENYL METALLOCENE COMPLEXES FOR OLEFIN POLYMERIZATION | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155659-B2 | Dimethyl-silyl-bridged-1-substituted-2-indenyl metallocene complexes for olefin polymerization | RPS10, ARL1, OR10J3 | KDR 1540/4885ADORA2A 4016/4885ADORA1 3690/4885 |
| US-20200115478-A1 | DIMETHYL-SILYL-BRIDGED-1-SUBSTITUTED-2-INDENYL METALLOCENE COMPLEXES FOR OLEFIN POLYMERIZATION | RPS10, ARL1, OR10J3 | KDR 1540/4885ADORA2A 4016/4885ADORA1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.